In vivo CAR-T double-knockout screen identifies NR4A1–SOCS3 as a synergistic gene pair
A high-throughput in vivo double-knockout CRISPR screen identified synergistic gene pairs that enhance CAR-T activity, with NR4A1–SOCS3 the leading pair. Dual knockout increased metabolic fitness and mitochondrial activity and supported potent antitumor activity and long-term control across multiple tumor models.

Background and open questions
CAR-T cell therapies have transformed treatment of certain hematological malignancies, but many patients relapse or fail to respond, often due to T-cell exhaustion and limited persistence. Single-gene knockouts such as PD-1 or CTLA-4 have shown incremental benefits, but whether pairs of genes could synergistically enhance CAR-T function remained systematically unexplored in vivo.
Study design
The investigators developed a high-throughput in vivo double-knockout CRISPR screening platform to systematically identify gene pairs whose combined loss enhances CAR-T cell function. The screen was performed in mouse tumor models using human donor-derived CAR-T cells. Top hits were validated individually and characterized for metabolic and mitochondrial parameters, then tested for antitumor efficacy across multiple tumor models versus non-targeting control sgRNA CAR-T cells.
Key results
- NR4A1–SOCS3 emerged as the leading synergistic gene pair from the screen.
- Dual knockout increased metabolic fitness and mitochondrial activity in CAR-T cells.
- NR4A1–SOCS3 double-knockout CAR-T cells showed potent antitumor activity and long-term tumor control across multiple tumor models (both solid tumors and hematological malignancies including B-ALL and mantle cell lymphoma PDX).
- The dual modification outperformed several benchmark single- and dual-gene modifications that had previously been reported in the literature, without worsening safety profile in mouse models (tissue pathology, serum cytokines, genome-wide sequencing showed no abnormalities).
Mechanistic interpretation
NR4A1 is a transcription factor associated with T-cell exhaustion, while SOCS3 negatively regulates cytokine signaling. Their combined loss appears to relieve multiple brakes on T-cell function simultaneously, resulting in enhanced metabolic capacity and sustained effector activity.
Limitations
- All data are preclinical; human safety, dosing, and efficacy are unknown.
- The reported model safety findings do not establish clinical safety; off-target effects of dual gene editing in human cells require further investigation.
- Long-term consequences of permanently removing these regulatory genes in humans remain to be studied.
- The full paper is not yet open access; analysis is based on abstract and extended data figures.
Authors and source
Nature (2026). Published online 4 November 2026. https://doi.org/10.1038/s41586-026-10956-z.
Numbers are as reported by the authors. Corrections: contact@
Related science
Regulatable IL-15 engineered TIL therapy in checkpoint-inhibitor-resistant melanoma: 67% ORR at the RP2D
OBX-115 expresses acetazolamide-regulatable membrane-bound IL-15, removing the need for exogenous IL-2
In vivo BCMA CAR-T phase 1: 15 months of follow-up, one ongoing sCR
Green CAR-T cells attacking a red myeloma cell at right
Targeting ZMYND8 increases effector-like exhausted T cells in mice and enhances immunotherapy responses
Green immune cells attacking red tumour cells
One email, with links to every paper. Reports and custom landscapes: contact@inlightbio.com.
Opens your email app with a pre-filled request; we add you by hand. Free, unsubscribe any time.


